Business Development
Licensing, Acquisitions, & Research Collaborations

Santen is a loyal and respected business partner with more than 125 years of experience in specialty ophthalmology pharmaceuticals and affiliates in all parts of the world. Collaborations are the primary way we fulfill our commitment — to fuel a pipeline of unique solutions for challenging unmet needs in ophthalmology and, in turn, to move closer to a future where permanent vision loss is a thing of the past.

We actively seek the following to help us deliver on our promise to ophthalmologists and their patients:


Why Partner with Santen


Current Areas of Interest for Business Development

Santen is especially interested in product candidates with a human or mechanistic target proof of concept, including:


Recent Business Development Alliances

2017

Strategic research collaboration with US-based twoXAR, Inc., an artificial intelligence-driven biotech company, focused on identifying new drug candidates for glaucoma. Santen will have exclusive rights to develop and commercialize resulting candidates.

Strategic 5-year collaboration to create a joint laboratory and to co-develop new technologies to address eye diseases, especially those prevalent in Asia. Expands our current research alliance and leverages and builds on key programs already underway.

Strategic research collaboration with RIKEN and the Foundation for Biomedical Research and Innovation, in Asia, to identify new drug candidates for photoreceptor degenerative diseases using iPS cell-derived retinal cells from RIKEN. Includes establishment of a research lab at FBRI.

Collaboration with University College London to conduct basic and translational ophthalmology research with scientists in the university’s Institute of Ophthalmology.

2016

Acquisition of InnFocus, Inc, US developer of Microshunt®, the first minimally invasive implant device and stand-alone procedure for primary open-angle glaucoma.

Exclusive license agreement whereby Santen will develop and globally commercialize ONO-9054, an FP/EP3 dual agonist for the treatment of glaucoma and ocular hypertension developed by ONO.

2014

Acquisition of Merck & Co, Inc.’s ophthalmology assets in Japan, Europe, and Asia Pacific.

License agreement for sales and marketing of ZIOPTAN® in the US market.

License agreement for developing TRC105, an anti-endoglin antibody for ophthalmology.

WANT TO PROPOSE AN OPPORTUNITY?

Connect With Us

MEET OUR
TEAM

View Leadership